FAKTOR OPTIONSSCHEIN - MODERNA | Delayed Deutsche Boerse AG 08:50:34 2024-06-26 EDT | ||
| 0.38 EUR | 0.00% |
|
| Current month | -26.92% | ||
| 1 month | -71.43% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-06-26 | 0.38 | 0.00% |
| 24-06-25 | 0.38 | 0.00% |
| 24-06-24 | 0.38 | +11.76% |
| 24-06-21 | 0.34 | -2.86% |
| 24-06-20 | 0.35 | +12.90% |
Delayed Quote Deutsche Boerse AG
Last update June 26, 2024 at 08:50 am
More quotesStatic data
| Product type | Productos Exóticos |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
BNP Paribas
|
| WKN | PG5MRN |
| ISIN | DE000PG5MRN5 |
| Date issued | 2022-09-29 |
| Strike | 137.6 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 50 € |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | EUR |
Technical Indicators
| Highest since issue | 289.7 € |
|---|---|
| Lowest since issue | 0.05 € |
| Spread | 0.01 € |
| Spread % | 2.50% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
137.6
USD
Average target price
145.9
USD
Spread / Average Target
+6.00%
- Stock Market
- Certificates
- Certificat
